CARGO Therapeutics, Inc. Overview
Pro stress-test →CARGO Therapeutics is a clinical-stage biotechnology company focused on developing chimeric antigen receptor (CAR) T-cell therapies for the treatment of cancer patients. The company advances next-generation cell therapies designed to overcome limitations of existing approved CAR T treatments, addressing challenges like tumor antigen loss, T-cell exhaustion, and treatment resistance.
Strategic Profile
Pro stress-test →The company's lead program CRG-023 is a tri-specific CAR T designed to target multiple B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector. CARGO continues advancing CRG-023 into Phase 1 trials and is developing its allogeneic platform while evaluating strategic options.
Competitive Landscape
Pro stress-test →Kyverna and Allogene Therapeutics are competitors of CARGO Therapeutics. The CAR T-cell therapy space is highly competitive with established players like Kite Pharma, Juno Therapeutics, and emerging companies addressing treatment-resistant cancers. CARGO's competitive positioning has weakened substantially following the clinical trial discontinuation.
Industry Context
CARGO Therapeutics, Inc. operates in Biotechnology - Cell Therapy / Oncology.
Key facts
Founded: 2019 · Headquarters: San Carlos, CA · Employees: 102 · Revenue: $0 · Market cap: $216M